.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on everyone market.The Eli Lilly-partnered biotech expect to list on the Nasdaq under the icon "BIOA," depending on to documentations filed along with the Stocks and Swap Compensation. The firm has actually not openly shared an expected monetary amount for the offering.The clinical-stage firm touts lead candidate azelaprag, a by mouth supplied small molecule slated to enter into stage 2 screening in combination with semaglutide-- offered by Novo Nordisk under trademark name Wegovy for weight reduction-- in the very first fifty percent of next year. Semaglutide is actually additionally sold as Ozempic and Rybelsus by Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually designed to incorporate effectively along with GLP-1 drugs, boosting fat burning while maintaining muscle mass. The investigational medication was actually found to be well-tolerated amongst 265 people throughout 8 stage 1 trials, depending on to BioAge.Formerly, BioAge got the help of Lilly to operate a test incorporating azelaprag along with the Huge Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetic issues as Mounjaro and also Zepbound for weight management. The partners are actually currently administering a phase 2 trial of azelaprag and tirzepatide, along with topline outcomes expected in the third fourth of 2025.The biotech is actually additionally preparing a blood insulin sensitivity proof-of-concept test evaluating azelaprag as a monotherapy in the initial one-half of upcoming year to assist prospective sign growth. Moreover, the company plans to inquire the FDA for authorization in the second fifty percent of 2025 to introduce individual screening for an NLRP3 prevention targeting metabolic diseases as well as neuroinflammation.BioAge's anticipated transfer to the public market complies with a mild uptick in intended biotech IPOs coming from Bicara Therapies and Zenas Biopharma. Zooming out, the latest IPO landscape is a "combined picture," along with premium providers still debuting on the general public markets, only in lessened varieties, depending on to PitchBook.